Equity Overview
Price & Market Data
Price: $0.978
Daily Change: -$0.0325 / 3.32%
Range: $0.972 - $1.02
Market Cap: $182,458,624
Volume: 283,221
Performance Metrics
1 Week: 1.29%
1 Month: -15.20%
3 Months: -26.50%
6 Months: -38.37%
1 Year: -39.87%
YTD: -3.67%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients. It is also developing TVGN 920 for treating cervical cancer; TVGN 960 for treating oropharyngeal cancer; TVGN 601 for treating MS; and TVGN 930 for treating EBV-associated lymphomas. The company was founded in 2020 and is headquartered in Warren, New Jersey.